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ABSTRACT: Respiratory complications are a common cause
of morbidity and mortality in amyotrophic lateral sclerosis (ALS).
Treatment of respiratory insufficiency with noninvasive ventila-
tion (NIV) improves ALS patients’ quality of life and survival.
Evidence-based practice guidelines for the management of ALS
patients recommend treatment of respiratory insufficiency with
NIV as well as consideration of insufflation/exsufflation to
improve clearance of airway secretions. Despite these recom-
mendations respiratory therapies remain underused. In this
review we provide a practical guide for the clinician to prescribe
and manage respiratory therapies for the patient with ALS.
Muscle Nerve 46: 313–331, 2012
Respiratory failure with or without pneumonia is
the most common cause of death in amyotrophic
lateral sclerosis (ALS).1,2 Reduced ventilation
results in part from respiratory muscle weakness
secondary to progressive motor neuron degenera-
tion. Respiratory muscle weakness is defined as the
inability of respiratory muscles to generate normal
levels of pressure and airflow during inspiration
and expiration.3 This leads to respiratory insuffi-
ciency, which is defined as inadequate pulmonary
ventilation to the point that gas exchange is
impaired, resulting in carbon dioxide retention,
hypoxemia, and frank respiratory failure.3,4 In gen-
eral, patients with ALS are able to compensate for
respiratory muscle weakness for a period of time,
but at some point they develop respiratory insuffi-
ciency and eventual respiratory failure.
Treatment of ALS patients with symptoms of re-
spiratory insufficiency with noninvasive ventilation
(NIV) appears to improve survival5–9 (Table 1) and
quality of life,10,11 which may be attributable to a
slower rate of pulmonary function decline.7,10,12
Supported by these data, both the 1999 and 2009
American Academy of Neurology (AAN) ALS prac-
tice parameters recommend consideration of NIV
treatment for ALS patients with significant respira-
tory muscle weakness.13,14 Despite recommenda-
tions made in 1999 by both the AAN and the
American College of Chest Physicians (ACCP),15
many ALS patients are not offered NIV therapy.16
Furthermore, despite recommendations about
when to use respiratory aids for ALS, little informa-
tion has been described in the literature about the
practical aspects of initiating and managing respi-
ratory therapies for ALS. The lack of literature that
addresses the practical aspects of ALS respiratory
care may make ALS clinicians reluctant to offer
and prescribe respiratory therapies. The goal of
this article is to provide a practical guide for the
ALS clinician on the use of respiratory assistive
devices and the prescription and management of
these therapies for ALS patients.
I. NONINVASIVE VENTILATION (NIV)
A. NIV: When to Start. There is little evidence of
explicit criteria on when NIV should be initiated,
and expert opinions on the topic vary consider-
ably. Nevertheless, the decision to prescribe NIV
should be based on a combination of evidence of
respiratory muscle weakness and respiratory
symptoms.
Respiratory Muscles. Normal human inspiration
at rest involves both the diaphragm and chest wall
muscles. The external intercostals,17 levator cos-
tae,18 and parasternal intercostals19 are active with
quiet breathing as measured by electrophysiology.
The chest wall muscles work to elevate the sternum
and ribs to expand both the anterior-posterior and
transverse diameters of the chest and lungs.20 Thus
human inspiration at rest is a combined effort of
both the diaphragm and chest wall muscles. In
contrast to the external intercostal muscles (inspi-
ration), the internal intercostal muscles depress
the ribs17 and compress the chest. Both the
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internal intercostals and abdominal muscles are re-
spiratory muscles of active expiration.
Although the force generated by the dia-
phragm versus other chest wall inspiratory muscles
cannot be measured in isolation with standard tests
of respiratory function (described in the next sec-
tion), some information can be gained by the dif-
ferences in motor innervation. The intercostal and
levator costae muscles are innervated by corre-
sponding intercostal nerves that originate from the
ventral thoracic nerve roots. The external intercos-
tals are innervated predominately by the upper
thoracic nerve roots, T2–6, while the diaphragm is
innervated by the C3–5 roots. Electrodiagnostic evi-
dence of denervation of T5 innervated paraspinal
myotomes, as well as the diaphragm, but not limb
muscles [biceps brachii (C5–6) and tibialis ante-
rior] demonstrate high specificity and positive pre-
dictive value for an abnormal forced vital capacity
<80% in ALS patients.21 Therefore, denervation of
the diaphragm, but also the upper thoracic myo-
tomes, which are known to innervate intercostal
muscles, is associated with reduced respiratory
function in ALS.
Measuring Respiratory Muscle Strength. To guide
initiation of NIV therapy it is important to assess
respiratory muscle strength. Respiratory muscle
weakness can be assessed easily with noninvasive
hand-held devices. The most common methods
include vital capacity (VC) (Fig. 1), maximum
inspiratory mouth pressure (MIP), and maximum
expiratory mouth pressure (MEP). Vital capacity
can be measured by 2 different methods: forced
vital capacity (FVC) and slow vital capacity (SVC).
With the FVC maneuver, the patient is instructed
to take a maximum inspiration, occlude the nares,
and then blow all the air out as fast and com-
pletely as possible. The slow vital capacity (SVC) is
similar in that the patient is instructed to maxi-
mally inspire, occlude the nares, and then blow all
the air out as completely as possible, but not as
fast as possible. With both maneuvers, the patient
exhales as much air as possible into a flow sensor.
If the patient has significant lip weakness, prevent-
ing an adequate seal around the tube, it is com-
mon to lose some of the exhaled volume, resulting
in an artificially low value. In this case, a mouth-
piece or facemask can be placed on the flow sen-
sor. The mouthpiece has a rubber flange that fits
between the teeth and lips to provide a better seal.
Table 1. Studies demonstrating survival benefit for ALS patients using NIV.
Author, year
Study
design NIV device NIV started Participants & treatments Findings
Pinto, 1995 NCT Bi-level PAP Daytime hypercapnia
or hypoxia
10 NIV 10 standard 3-year survival higher with
NIV (87.5% vs 22.2%, P < .004)
Aboussouan,
1997
Obs BiPAPV
R
;
ST mode or
PLV-100
Daytime orthopnea,
hypercapnia or both
21 NIV 4h nocturnal
18 intolerant
Median survival 2 months in
those NIV intolerant, 15 months
NIV tolerant (P < 0.001)
Kleopa, 1999 Obs Bi-level PAP Respiratory symptoms,
FVC <50% predicted,
or FVC drop >15%
in 3 months
38 NIV>4h/d 32
NIV<4h/d 52
refused NIV
Mean survival 14.2 mo >4h/d(p<0.001),
7.0 mo <4 h/d (P ¼ 0.038),
4.6 mo refused NIV
Gruis, 2006 Obs Bi-level PAP;
S mode
Respiratory symptoms and
FVC <50% or MIF
<60 cm water
18 NIV 4 h/nocturnal
19 intolerant
NIV tolerant decreased risk of
death (HR 0.23) 95% CI (0.10,0.54)
Bourke, 2006 RCT VPAPV
R
STII;
ST mode
Orthopnea & MIP <60%
or hypercapnia
22 NIV 19 standard Median survival benefit 205 days
with NIV (P ¼ .006).
NCT, nonrandomized controlled clinical trial; Obs, observational study; RCT, randomized controlled clinical trial; NIV, noninvasive positive-pressure ventila-
tion; PAP, positive airway pressure; FVC, forced vital capacity; MIP, maximum inspiratory pressure; MIF, maximum inspiratory force (MIP, MIF, or negative
inspiratory force are often used interchangeably); PLV-100, volume-controlled portable ventilator in assist-control mode (Life Care Products, Lafayette, CO);
BiPAP
VR
(Respironics, Inc., Murrysville, PA); VPAP
VR
STII (ResMed, UK Ltd, Abingdon, UK); ST, spontaneous timed mode; S, spontaneous mode; HR, haz-
ard ratio; CI, confidence interval; cm, centimeters; h, hours; mo, months.
FIGURE 1. Lung Volumes.
314 Respiratory Therapies for ALS MUSCLE & NERVE September 2012
Two common mouthpieces include the AirLifeTM
adult rubber mouthpiece, and the ComFitTM dis-
posable mouthpiece. The MIP and MEP are meas-
ured starting at functional residual capacity (FRC)
(Fig. 1) at the end of expiration of quiet breath-
ing. At FRC the outward pull of the chest wall is
balanced against the inward pull of the lungs.
Thus measurement of MIP at FRC reduces any
overestimate of pressure change from chest wall
recoil to get the most accurate measurement of re-
spiratory muscle force.22 The MIP is performed by
having the mouth occluded with a mouthpiece
connected to a pressure transducer. The patient
then expires through the nose, and the nares are
then occluded while the patient performs a maxi-
mum inspiratory effort for 2–3 s. The MEP is per-
formed in the same manner, only the nares are
occluded, and maximum expiratory effort is per-
formed for 2–3 s. The peak inspiratory pressure
over one second is the recorded MIP, and the
peak expiratory pressure over 1 s is the MEP. The
maneuver is repeated 3 times or until 2 similar
measurements obtained, as the patient may have
learned improvement with the MIP/MEP proce-
dure. The MIP and MEP are designed to be iso-
metric measurements of inspiratory and expiratory
muscle force. Respiratory efforts against an
occluded circuit can be uncomfortable and awk-
ward, and therefore artificially low measures may
be obtained. Also, some patients with significant
respiratory muscle weakness may be able to gener-
ate considerable pressure with their mouth
muscles. This may lead to overestimation of MIP
or MEP. A different, but complementary test to
the MIP is the maximal sniff nasal pressure
(SNIP). With the SNIP, a plug is placed in 1 nos-
tril, the patient breathes normally with the mouth
closed and then the other nostril is occluded while
the patient performs 10 maximum sniffs. Sniffing
maneuvers are more reproducible than the sus-
tained efforts used for measuring MIP, and prob-
lems related to mouth weakness are avoided. The
FVC and SVC are measured with a spirometer and
are adjusted for age, gender, and height. They are
displayed as the actual value in liters and the
adjusted value as the percent predicted. The MIP
and SNIP are also recorded as the exact value with
negative centimeters (cm) of H
2
O for MIP and
positive cm of H2O for MEP. The MIP, MEP, and
SNIP are affected by gender and age and may also
be presented as percent predicted. Normal ranges
based on age and gender for MIP, MEP and SNIP
are found in Table 2.22 It is worth noting that
other studies of MIP and MEP have yielded a large
range for normal values.23
FVC measured in the upright position can
detect mild respiratory muscle weakness early in
the disease course, as 71–85% of ALS patients have
an abnormal FVC (<80%) at the time of presenta-
tion.24–26 However, supine FVC27 and MIP appear
to decrease earlier in the ALS disease course than
upright FVC.25,28 ALS patients with respiratory
symptoms have lower mean FVC than those with-
out respiratory symptoms, 56% vs. 76%.25 However,
Fallat et al. demonstrated that as many as 64% of
ALS patients with an FVC <50% may have mild or
no significant respiratory symptoms.24 Therefore,
as early as the late 1970s, it was recommended that
spirometry, including vital capacity, be measured
serially in ALS patients to detect respiratory muscle
weakness irrespective of symptoms.
There is considerable debate about which mea-
sure of respiratory muscle weakness will optimally
detect impending respiratory insufficiency. The cli-
nician may be compelled to start NIV before day-
time hypercarbia or symptomatic respiratory mus-
cle weakness ensues to prevent or delay this
occurrence. However, there are no randomized
controlled studies that address whether starting
NIV therapy earlier, before daytime hypercapnia or
symptoms of orthopnea, is beneficial to prevent re-
spiratory failure or to prolong survival. It also may
be quite possible that ALS patients without respira-
tory symptoms may abandon NIV therapy. Both
the SVC <50% predicted and MIP 25% predicted
have high specificity, 89%, and 83% respectively,
in predicting hypercarbic respiratory failure, but
lower sensitivity, 53% and 55%, respectively.29 If
the MIP cutoff for predicting respiratory failure
were increased to 45% of predicted, the specificity
of the test dramatically decreased to 56%. A SNIP
<32% of predicted had similar specificity, 85%,
but with higher sensitivity, 81%, in predicting cur-
rent hypercarbic respiratory failure.29 However,
Table 2. Normal Values for MIP, MEP and SNIP.
Age
MIP cm H20
Mean (SD),
[<60% predicted]*
MEP cm
H20
Mean (SD)
SNIP cm
H20 Mean (SD),
[<32% predicted]†
Men:
20-35 110 (27), [65] 128 (32) 117 (30), [37]
36-50 105 (21), [62] 132 (34) 105 (25), [33]
51-65 104 (22), [61] 129 (22) 112 (16), [35]
66-80  83 (23), [49] 103 (32) 91 (22), [28]
Women:
20-35  78 (18), [46] 84 (16) 84 (15), [26]
36-50  87 (21), [51] 95 (25) 94 (21), [29]
51-65  80 (17), [47] 81 (16) 84 (18), [26]
66-80  58 (16), [34] 69 (18) 76 (11), [24]
Normal values.22
*Orthopnea and MIP <60% predicted used as criteria to start NIV in a
randomized controlled study.9
†SNIP <32% predicted associated with 85% specificity and 81% sensi-
tivity in predicting hypercarbic respiratory insufficiency.29
MIP, maximum inspiratory pressure; MEP, maximum expiratory pressure;
SNIP, maximal sniff nasal pressure; SD, standard deviation.
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when a diagnostic test has a higher sensitivity, it
also is more likely to include false positive results;
therefore, the positive predictive value (PPV) or
proportion of subjects with a positive test result
who are correctly diagnosed becomes a more use-
ful assessment of test precision. The positive pre-
dictive value (PPV) or the proportion of ALS
patients with an abnormal SNIP or SVC who are
correctly diagnosed with hypercarbic respiratory
insufficiency is essentially the same: SNIP <32%
PPV ¼ 68% and SVC <50% PPV ¼ 67%.29 The
SNIP therefore becomes more useful to rule out
hypercarbic respiratory failure when the SNIP is
>32%. Importantly, no test of respiratory muscle
strength (SVC, MIP, MEP, or SNIP) had significant
positive predictive power to detect hypercarbic re-
spiratory insufficiency in those ALS patients with
significant bulbar dysfunction.29 Others have indi-
cated the SNIP actually underestimates inspiratory
muscle strength, as the mean MIP remains higher
than the mean SNIP in ALS patients with moder-
ately severe respiratory impairment, with a mean
VC around 50%.30 The 2 tests measure inspiratory
muscles in different ways; the SNIP is a fast con-
traction, while the MIP is a sustained isometric
contraction of inspiratory muscles.30 Isometric
muscle force of limb muscles is a standard measure
of muscle function for ALS,31 thus isometric meas-
ures with MIP and MEP would suggest a meaning-
ful measurement of respiratory muscle function.
Additionally, while a low SNIP (<40 cm H
2
O) is
recommended as a trigger to consider starting NIV
in the more recent 2009 AAN practice parame-
ter,14 it is not a measure supported by evidence
from a randomized controlled study. It is not cur-
rently recommended by the American College of
Chest Physicians (ACCP) and is not recognized as
a trigger for NIV by Medicare guidelines.
ALS Patient Symptoms and Measures of Respiratory
Muscle Function at NIV Initiation. Initial studies of
NIV for ALS report beginning NIV when patients
have either (1) objective evidence of respiratory
insufficiency with daytime hypercapnia, (2) respira-
tory symptoms including orthopnea, or (3) FVC
<50% or 15% drop in FVC over a 3-month period
(Table 1).5–7 All 3 studies published in 1999 or
earlier (Table 1) reported improved survival in
ALS patients who were tolerant to NIV therapy.
However, 1 study was retrospective, and the other
2 prospective studies did not randomize patients to
NIV treatment. Nevertheless, these findings were
compelling enough that the 1999 AAN practice pa-
rameter provided a guideline recommending that
NIV be provided to ALS patients with respiratory
symptoms or FVC <50%.13 Additionally, the ACCP
provided a consensus recommendation in 1999
that NIV be initiated for patients with ALS (and
several other neuromuscular disorders) with symp-
toms of ‘‘fatigue, dyspnea, morning headache,
etc.’’ and one of the following: hypercapnia with
PaCO2 (partial pressure of arterial carbon dioxide)
45 mmHg, nocturnal oximetry demonstrating ox-
ygen saturation 88% for 5 consecutive minutes,
MIP <60 cm H2O, or FVC <50% predicted.15
Importantly, the ACCP guidelines for initiating
NIV were adopted by Medicare and subsequently
other medical insurance providers. Therefore in
ALS, documentation of symptoms of respiratory
muscle weakness and 1 of the aforementioned
abnormal objective physiologic measurements of
respiratory muscle weakness are required for the
initial prescription of NIV. It is important for the
ALS clinician to know that a polysomnogram
(sleep study) is NOT required to start NIV in ALS
patients who meet the criteria outlined by the
ACCP.
In an attempt to determine the optimal meas-
urements of respiratory muscle weakness to guide
initiation of NIV and optimize quality of life and
NIV compliance, Bourke et al. prospectively fol-
lowed ALS patients with periodic VC, MIP, MEP,
SNIP, daytime arterial blood gas and polysomno-
grams for 1 year.10 ALS patients were offered NIV
if they met any one of the following criteria:
(1) orthopnea (supine breathlessness), (2) daytime
sleepiness or unrefreshing sleep in the presence of
sleep-disordered breathing or respiratory muscle
weakness with MIP and SNIP <80% predicted,
(3) daytime hypercapnia with PaCO2 >45 mmHg,
(4) nocturnal oxygen desaturation with SaO2 (oxy-
gen saturation) <90% for 5% of the night, or
(5) apnea-hypopnea index >10 events per hour of
sleep. The study demonstrated that orthopnea was
the symptom associated with the most significant
improvement in quality of life, while sleep symp-
toms were less specific. The apnea-hypopnea index
was not at all useful to guide initiation of NIV
treatment.10 Therefore, daytime sleepiness and
poor sleep are not always associated with respira-
tory muscle weakness, and the clinician should
interpret these symptoms with some caution.
Some experts have suggested that nocturnal ox-
ygen desaturation is an early finding of respiratory
muscle weakness and precedes significant daytime
respiratory symptoms and hypercarbia. ALS
patients who were started on NIV after demonstrat-
ing a small drop in nocturnal oxygen saturation
(4% below the mean nocturnal oxygen saturation)
with normal arterial blood gas assessment had
improved survival compared with historical con-
trols who were started on NIV with an abnormal
arterial blood gas.32 This suggests that an individ-
ual with a mean nocturnal oxygen saturation of
96% who drops to 92% should be started on NIV.
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It is difficult to believe that such a small change in
oxygen saturation is clinically meaningful. Perhaps
the findings could be attributed simply to starting
NIV before development of an abnormal arterial
blood gas measurement. Additionally, at least 1
study has demonstrated that ALS patients with or-
thopnea, a symptom that would suggest NIV initia-
tion would improve quality of life, reported no
abnormal drop in nocturnal oxygen saturation
(abnormal measured as <90% for  5% of the
night).10 Furthermore, the same study demon-
strated that all ALS patients with abnormal noctur-
nal oxygen saturation also reported orthopnea,
and several ALS patients with orthopnea did not
have abnormal nocturnal oxygen desaturation.10
This latter finding suggests that significant noctur-
nal oxygen desaturation did not precede develop-
ment of orthopnea. Taken together, these findings
indicate that nocturnal oxygen desaturation is
unlikely to provide additional information to the
clinician on when to initiate NIV. Lastly, in terms
of practicality, Medicare uses the ACCP guideline
for nocturnal oxygen desaturation, <88% for 5 sus-
tained min, to prescribe NIV for ALS. Therefore, a
small drop in nocturnal oxygen saturation in isola-
tion will not allow for NIV initiation by Medicare
guidelines.
The first randomized controlled study of NIV
for ALS patients used a primary outcome of quality
of life and secondary outcome of survival.9 Forty-
one ALS patients were admitted to the hospital
and randomized to NIV or standard of care treat-
ment if they had symptoms of orthopnea and a
MIP <60% predicted, or symptoms associated with
daytime hypercapnia PaCO2 >45 mmHg. Patients
in the NIV group had a significant improvement
in quality of life and a median survival benefit of
205 days (nearly 7 months).9 Although VC was not
used as a criterion to initiate NIV, the mean VC
was only 56% in the NIV group and 49% in the
standard of care group at the time of treatment
randomization, indicating that these ALS patients
had significant reductions in VC. Furthermore, it
is important to note that the randomized con-
trolled study used an MIP of <60% predicted, not
an absolute MIP <60 cm H
2
O. For many patients
over the age of 65, a normal MIP may be around
50 cm H
2
O for women or 80 cm H
2
O for men
(Table 2),22 corresponding to a <60% predicted
MIP of around 30 to 47 cm H
2
O, a value much
lower than the guideline from the ACCP’s MIP
(<60 cm H2O). Importantly, this value (<60
cm H
2
O) was not supported by a randomized con-
trolled study. Additionally, the evidence demon-
strating a survival advantage for ALS patients using
NIV applies to patients with significant respiratory
muscle weakness with a mean FVC ¼ 56%, MIP ¼
31% predicted, and SNIP ¼ 23% predicted.9 It
remains uncertain whether initiating NIV when
patients are without daytime hypercarbia or or-
thopnea and with an MIP >60% predicted
improves survival. Randomized controlled studies
are needed to address this question, particularly
since retrospective or nonrandomized studies have
suggested that starting NIV earlier in the disease
course may improve outcomes.12,32,33
Conclusions
1 ALS patients should have VC (FVC or SVC),
MIP, and MEP assessed approximately every 2–4
months irrespective of respiratory symptoms.
Supine FVC should be considered, as it can
detect milder respiratory muscle weakness.
2 SNIP may also be considered, as a SNIP >32%
likely excludes the diagnosis of hypercarbic re-
spiratory insufficiency but is not a replacement
for MIP.
3 NIV should be offered if an ALS patient has (1)
orthopnea and MIP <60% predicted or (2)
PaCO2 45 mmHg and symptoms related to
hypercapnia.
4 NIV should be considered in ALS patients with
(1) symptoms of orthopnea or respiratory mus-
cle weakness and (2) MIP <60 cm H2O or FVC
<50%.
5 NIV should be considered in ALS patients with-
out respiratory symptoms and an FVC <50%.
6 Nocturnal oxygen saturation and polysomno-
gram do not appear to provide additional infor-
mation beyond an assessment of respiratory
symptoms and tests of respiratory muscle
strength (FVC and MIP) in deciding whether to
initiate NIV for ALS patients.
B. NIV Device Type. Bi-level Positive Airway Devi-
ces. Bi-level positive airway pressure (PAP)
machines are the most commonly used devices to
manage respiratory weakness in ALS and are the
best studied (Table 1). Bi-level PAP machines are
often referred to by trade names. Examples
include the following: BiPAPV
R
(Philips Respironics,
Inc., Murrysville, PA) and VPAPV
R
(ResMed Corp,
San Diego, CA). The machines are set to deliver a
specific inspiratory airway pressure (IPAP) and ex-
piratory airway pressure (EPAP), similar to a pres-
sure-controlled mechanical ventilator. The differ-
ence in pressure between IPAP and EPAP
represents the level of pressure support. Thus,
identical absolute increases in IPAP and EPAP do
not alter the pressure support provided. Typically,
bi-level PAP has 2 modes: spontaneous (S) and
spontaneous/timed (ST). In both the S and ST
mode, the bi-level PAP is triggered to provide
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IPAP when the user generates a small inspiratory
flow. The machine then provides the IPAP to sup-
port inhalation for a maximum of 3 seconds, or
when air flow significantly decreases, indicating the
end of inspiration, and the machine returns to
EPAP. For the most part, the trigger for cycling
from IPAP to EPAP is pre-set and cannot be
changed by the clinician or patient. The patient’s
spontaneous breathing drives the machine to cycle
between IPAP and EPAP, and this provides some
degree of comfort and control over the NIV de-
vice. In the ST mode, the machine works as
described in the S mode but additionally can pro-
vide a machine-triggered breath if the patient falls
below the minimum number of breaths per mi-
nute, as set by the clinician. In the ST mode, the
provider can set the duration of the machine-trig-
gered breath, but the IPAP pressure setting deliv-
ered by the machine or the patient’s spontaneous
breathing is the same. It is our experience that
many ALS patients can trigger the bi-level PAP
machine in the S mode and may not require
machine-triggered breaths in the ST mode. How-
ever, some patients may have abnormal central re-
spiratory drive and will benefit from having a set
backup respiratory rate. Also, patients with very
severe inspiratory muscle weakness may not be
able to trigger the bi-level PAP machine and will
require a set rate. The clinician must make the
family aware that the NIV machine set in ST mode
will continue to provide assisted breaths to an ALS
patient after death. We have had patients die in
their sleep, yet the family was unaware, as the NIV
machine continued to cycle as if the patient was
breathing. Although bi-level PAP machines were
used in the ST mode in several studies including a
randomized controlled trial,6,9 no information was
provided on machine-triggered breaths or the rate
used. A least 1 observational study demonstrated a
survival benefit in those tolerant of bi-level PAP
using the S mode (Table 1).8 There are no
randomized controlled studies comparing different
modes or types of bi-level PAP devices for ALS.
Autotitrating NIV devices are relatively new and
designed as alternatives to standard bi-level PAP.
With the autotitrating NIV, the clinician can spec-
ify a target tidal volume and a range for the maxi-
mum and minimum IPAP. Examples of the auto-
titrated NIV include the BiPAPV
R
AVAPS (Phillips
Respironics), AutoVPAPV
R
(ResMed), and the Tril-
ogy mechanical ventilator (Phillips Respironics) in
the AVAP mode. In theory, the auto-titrated NIV
may have advantages with respect to NIV tolerance
by providing only the IPAP required to support
the target tidal volume. Additionally, in asymptom-
atic patients, this provides an objective target for ti-
tration. However, in a randomized cross-over study
comparing standard bi-level NIV with auto-titrated
NIV in patients with respiratory insufficiency from
neuromuscular disease, the auto-titrated NIV pro-
vided less ventilatory support with a statistically sig-
nificant decrease in mean minute volume ventila-
tion and an increase in mean carbon dioxide.
Furthermore, the auto-titrated NIV was not associ-
ated with improved patient self-reported toler-
ance.34 Thus far, there is no clear advantage for
using auto-titrated NIV over standard NIV for re-
spiratory insufficiency from neuromuscular disease.
Portable Ventilators. When portable ventilators
capable of volume cycled ventilation are used, the
term mechanical ventilation is typically applied.
Mechanical ventilation with a portable ventilator
can be used non-invasively just like a bi-level PAP
machine or invasively with a tracheostomy in the
outpatient setting. Portable ventilators can be set
to provide the patient with a set amount of pres-
sure (pressure support ventilation) or a set amount
of volume (volume controlled ventilation) with
each breath. Experts debate whether pressure sup-
port or volume controlled mode is best for
patients with ALS, but there is no evidence to sup-
port one over the other. A randomized cross-over
study exposed patients with hypercarbic respiratory
insufficiency from a variety of disorders to both
pressure and volume controlled NIV with mechani-
cal ventilators. Both modes significantly improved
gas exchange as measured by arterial blood gas,
and the patients indicated no preference for pres-
sure or volume controlled NIV.35 There are no
randomized, controlled studies that compare bi-
level PAP machines and portable ventilators. One
study from 1997 reported ALS patients chose a bi-
level PAP device when given the option of bi-level
PAP or volume-controlled ventilator.6 However,
since 1997, portable ventilators and bi-level PAP
devices have evolved. The portable ventilators have
become smaller and more user-friendly than the
devices that existed a decade ago.
While portable ventilators are more compli-
cated than bi-level PAP machines in regard to ease
of set-up, these devices do allow for more options
in administration of NIV. The portable ventilator
allows for more control of the flow trigger and
inspiratory and expiratory time. The flow trigger
allows for more sensitivity and thus less air move-
ment on the part of the ALS patient to trigger the
ventilator for a breath. The inspiratory and expira-
tory time adjustments allow more control as to
how long the ALS patient receives positive airway
pressure during each phase. For example, patients
may be accustomed to taking small, frequent
breaths, and if they are suddenly forced to take
less frequent but larger breaths with NIV, they may
be uncomfortable. It is unclear if these additional
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adjustments with a portable ventilator offer mean-
ingful advantages to the ALS patient over a bi-level
PAP machine, aside from comfort in some cases.
Portable ventilators come with an internal bat-
tery that allows the user more freedom with the de-
vice, while the bi-level PAP machines must use an
external battery pack or power adapter if they are
used in a motor vehicle. If an ALS patient uses the
bi-level PAP throughout the night and day, power
failure of the device could lead to death.36 Both
the bi-level PAP and portable ventilator can be
attached to a power wheelchair with the appropri-
ate brackets, and the wheel chair battery can be
used as a power source. The clinician should con-
tact the ALS patients’ wheel chair provider to
order these attachments.
Oxygen Therapy. Importantly, oxygen therapy
has been demonstrated to worsen respiratory symp-
toms and carbon dioxide retention in patients with
neuromuscular respiratory insufficiency, resulting
in hypercapnic coma or respiratory arrest.37 Sup-
plemental oxygen as low as 0.5 to 2 L/min has
been demonstrated to exacerbate carbon dioxide
retention.38 ALS patients who may require oxygen
therapy for a non-ALS diagnosis such as pulmo-
nary or cardiac disease should use oxygen in con-
junction with NIV.
Conclusions
1 Bi-level PAP devices used in the spontaneous/
timed or spontaneous mode for ALS patients
with symptomatic respiratory muscle weakness
are associated with a survival benefit.
2 The spontaneous/timed mode requires the pro-
vider to set the breaths per minute (BPM) rate.
If this mode is selected, a standard initial rate of
6–10 BPM is a reasonable value to avoid discom-
fort from excessive machine-triggered breaths,
but it should be titrated to the individual.
3 Portable ventilators capable of volume cycled
ventilation are an alternative to bi-level PAP
machines to administer NIV to ALS patients.
4 ALS patients who rely on NIV need to have an
alternative power source available. ALS patients
and caregivers should know how to contact an
on-call respiratory therapist to assist with any dys-
function of an NIV device.
5 Oxygen therapy is not needed and should be
avoided in nearly all ALS patients with respira-
tory insufficiency.
C. NIV- How to Start and Titrate. Background. To al-
leviate dyspnea or orthopnea, NIV must provide
enough support to off-load the work of breathing.
Initial settings are often relatively low, with an
IPAP of 8–10 cm of H
2
O and EPAP of 3–5 cm H2O
to allow the patient to become accustomed to
NIV.39 The IPAP is then increased as needed to al-
leviate symptoms or improve gas exchange as meas-
ured by arterial blood gas while maintaining
patient tolerance to NIV.9 The normal respiratory
system only needs to decrease intrathoracic pres-
sure by 5 cm H
2
O for adequate airflow with inspi-
ration.40 Therefore, applying 4–5 cm H
2
O pressure
support to the system is reasonable to assist weak-
ened muscles of inspiration, assuming chest wall
and lung compliance are relatively normal. If these
structures have decreased compliance, the patient
will require higher pressure support. However, if
the provider increases the pressure support beyond
what is needed to support quiet breathing, the
patient may feel uncomfortable secondary to over-
inflation of the lungs. At the time NIV is started,
patients may be using accessory respiratory
muscles, such as the sternocleidomastoids, with
quiet breathing in addition to routinely used
inspiratory muscles: the diaphragm and external
intercostal muscles.27 Accessory muscle use often
abates in the upright and supine positions with
NIV, demonstrating its effectiveness.6,41
Where to Start NIV. In the only randomized
controlled study of NIV for ALS, patients were
admitted to the hospital for NIV initiation.9 We
have successfully admitted ALS patients to the hos-
pital to titrate NIV. Evaluation and treatment of re-
spiratory insufficiency is a valid reason for hospital
admission and insurance approval. One alternative
is titrating NIV for the ALS patient in a sleep labo-
ratory. As discussed above, polysomnography plays
no significant role in determining when to start
NIV, but it may be used to guide titration of initial
NIV pressure settings. This would require signifi-
cant discussion with the sleep laboratory staff
whose typical obstructive sleep apnea patient popu-
lation is ambulatory without motor disabilities.
Although portable, in-home polysomnography with
oxygen saturation and transcutaneous carbon diox-
ide measurements are not readily available in the
United States; these evaluations are performed in
Europe.34 When patients with neuromuscular dis-
orders requiring NIV were given the option of
titrating NIV in a sleep laboratory or at home, the
majority of patients chose home polysomnogra-
phy.34 This finding is congruent with our experi-
ence that ALS patients are quite reluctant to spend
a night in the sleep lab and prefer NIV initiation
at home. The American Academy of Sleep Medi-
cine has proposed best practices guidelines for the
titration of NIV in a sleep laboratory for patients
with stable hypoventilation syndromes.42 The ALS
clinician should keep in mind that a sleep labora-
tory would not be appropriate for unstable ALS
patients, and hospital admission would be advised.
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Additionally, the sleep laboratory may not have
readily available appointments to accommodate
ALS patients who require urgent NIV titration.
One study demonstrated that nearly one-third of
ALS patients started NIV therapy emergently.43
Importantly, emergent NIV initiation was not asso-
ciated with poorer survival when compared with
those ALS patients with nonemergent NIV
initiation.43
A third alternative is initiating NIV in the out-
patient clinic or home setting by the ALS clinician
or respiratory therapist under ALS clinician direc-
tion. Observational studies have demonstrated that
NIV initiated as an outpatient is associated with a
survival benefit in those tolerant to NIV
treatment.6,8
NIV Pressure Settings. Little detailed informa-
tion about titration of NIV for ALS has been pub-
lished. In a randomized controlled study, initial
NIV settings were selected to ‘‘optimize’’ nocturnal
oximetry, ‘‘attempt to normalize’’ daytime gas
exchange as measured by arterial blood gas
(ABG), and maintain ALS patient tolerance to
NIV.9 No further description or results of oximetry
were presented. In the same prospective study, af-
ter NIV initiation, subsequent titration was guided
by daytime ABG and patient tolerance, but not
nocturnal oximetry.9 Therefore the utility of noc-
turnal oximetry appears to be limited for monitor-
ing NIV therapy. Additionally, in ALS one would
expect measurement of nocturnal hypercapnia
may be a more effective indicator of nocturnal ven-
tilation support. In a retrospective study, NIV start-
ing at 8 cm of H2O IPAP and 4 cm of H2O EPAP,
with the IPAP increased as directed by patient
symptoms, was associated with increased survival in
those who tolerated the NIV despite the lack of
ABG or oxygen saturation monitoring.8 Interest-
ingly, pressure adjustments were often made early
within the first year of use, although 4 of 18 toler-
ant subjects found the original pressure settings to
be adequate for the duration of NIV use until
death.8 No study has compared efficacy of NIV in
those titrated by ABG, comfort, nocturnal oxime-
try, or capnography.
Titrating NIV to normalize daytime gas
exchange as measured by ABG may be optimal.
Nocturnal NIV has been demonstrated to improve
daytime arterial hypercarbia and hypoxia in ALS
patients.44 Thus nocturnal measurements of gas
exchange may not be required. However, not all
ALS clinics are able to measure an ABG in the out-
patient setting easily, and ALS patients may refuse
this painful procedure. Monitoring daytime
exhaled end-tidal carbon dioxide or transcutane-
ous carbon dioxide with a capnograph may be a
practical alternative. A capnograph is easy to use,
relatively inexpensive, and portable, and it allows
for convenient assessments in clinic or even in the
patient’s home. The disadvantage to end-tidal car-
bon dioxide measurement is that the accuracy may
be limited when it is measured while the patient is
using NIV, as increased airflow may artifactually
dilute the exhaled concentration of carbon diox-
ide. Transcutaneous carbon dioxide is measured
with a more expensive type of capnograph, where
an infrared sensor is placed on the skin over a
bony prominence or ear lobe such that measure-
ments can be made while NIV is in place. In
hemodynamically stable adults, transcutaneous car-
bon dioxide assessments correlated well with ABG
partial pressure carbon dioxide measurements over
a range of 26 to 71 mmHg.45
A possible alternative to using arterial blood
gas assessment to guide NIV titration is to titrate
NIV to maintain an adequate volume of ventilation
based on weight. It has become a standard
accepted value that a normal tidal volume in
humans is around 6–8 ml/kg, and optimal minute
ventilation to maintain appropriate gas exchange
is 6 L/min. The minute ventilation is simply the
tidal volume times the respiratory rate. Unfortu-
nately, most standard bi-level PAP type NIV
machines do not measure user tidal volume or mi-
nute ventilation, but portable ventilators, even
when used noninvasively, can record both values.
Conclusion
1 It is reasonable to begin NIV with 8 cm H2O
IPAP and 4 cm H2O EPAP and increase the
IPAP to alleviate symptoms, or to select the ini-
tial pressure based on improvement in daytime
ABG and oximetry together with patient
comfort.
2 Once initiated, NIV pressures should be titrated
to comfort or daytime ABG.
3 When titrating to comfort, increases in IPAP of
2 cm H2O are reasonable for each adjustment.
4 Increased NIV requirements are likely with time,
and thus breathing comfort should be assessed
serially.
D. NIV-Mask Interfaces. NIV mask interfaces
include all those available for use with continuous
positive airway pressure (CPAP). These interfaces
are divided into 4 categories: nasal masks, nasal pil-
lows/prongs, oronasal masks, and oral masks.
Nasal masks are triangular in shape and fit over
the entire nose, often with a portion of the mask
resting on the forehead (Fig. 2). The mask is then
held in place with straps around or a bracket over
the head. Nasal pillows are tubes that fit onto the
external nares (Fig. 3). The oronasal mask is often
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referred to as a full face mask, as it fits over the
nose and mouth (Fig. 4). The oral mask is used
only by means of the mouth and is not often used
in ALS patients given the frequency of bulbar
dysfunction.
There are no randomized controlled studies
that compare any of the interfaces with respect to
patient preference or tolerance in ALS. However,
in a randomized controlled study comparing NIV
to standard of care without NIV, both nasal and
nasal oral masks were used.9 Literature reviews of
the obstructive sleep apnea population demon-
strate that nasal pillows are reported to be more
comfortable than nasal masks.46 In a study of
patients with hypercapnic respiratory insufficiency
from either pulmonary or neuromuscular disorders
who receive NIV with a mechanical ventilator, the
nasal mask, nasal pillows, and oronasal mask inter-
faces were each used for a brief time period to
assess mask preference and ABG improvement.35
All 3 mask types were associated with improved ox-
ygenation and decreased hypercarbia, although it
was slightly better with the nasal pillows and full
face masks. In the same study, the nasal mask had
the highest patient acceptance over the nasal pil-
lows and full face mask.35
Headgear must be considered with respect to
not only comfort, but also ease of placement and
removal. Some headgears, such as those with a sin-
gle piece head frame, are more conducive to one-
handed operation than those with multiple straps.
Although no studies have addressed this issue in
ALS, the topic has been considered in stroke
patients. In the acute stroke population, a group
that may have significant upper limb weakness,
patients were much quicker at placing and remov-
ing a single head frame headgear than a headgear
with straps. Ease of use, however, did not necessar-
ily correspond to comfort.47
We often use a nasal pillow system initially for
comfort given that these mask interfaces have the
least contact with the face. Nasal pillow systems
that we have found to be successful include the
SwiftTM FX (ResMed) (Fig. 3A), as it is very light
weight with minimal pressure on the face and a
minimal amount of straps on the head. This
SwiftTM FX is improved over the previous Mirage
SwiftTM II in that the tubing easily rotates with less
chance of the tubing getting caught in the bed
clothes and dislodging the interface. The OpusTM
360 (Fisher & Paykel Healthcare) (Fig. 3B) nasal
pillow system is similar to the SwiftTM FX system as
FIGURE 2. Nasal masks. (A) MirageTM FX (ResMed); (B) ZestTM (Fisher & Paykel Healthcare); (C) Breeze
VR
SleepGear
VR
nasal mask
(Covidien-Puritan Bennett).
FIGURE 3. Nasal pillow masks. (A) SwiftTM FX (ResMed); (B) OpusTM 360 (Fisher & Paykel Healthcare); (C) Breeze
VR
SleepGear
VR
nasal pillows (Covidien-Puritan BennettTM).
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a small nasal pillow system with tubing that can
freely rotate. We have also had success with the
BreezeV
R
SleepGearV
R
(Covidien-Puritan BennettTM)
(Fig. 3C) nasal pillow system that uses a bracket
rather than straps to secure to the head and can
often allow the user to put the system in place
with one limb. The nasal pillow systems are also
small enough to allow patients to wear eye glasses
while the mask is in place. In our experience,
some patients find the nasal pillow systems irritate
the nose, are not secure enough to the face or
head, or just seem to leak despite adjustments. In
these situations, we use a nasal mask.
The nasal mask systems have more pressure
points on the face, are generally larger than a
nasal pillow system, and usually require a piece of
the mask to go over the bridge of the nose such
that the patient cannot wear eye glasses. We have
had success with the ZestTM (Fisher & Paykel
Healthcare) (Fig. 2B). Many find it to be quite
comfortable, as it uses a foam cushion that seems
to be lighter than the gel or silicone cushions used
in other nasal masks. The MirageTM FX (ResMed)
(Fig. 2A) is a new mask that is lightweight with a
very thin piece that goes over the bridge of the
nose that we have found useful. The BreezeV
R
SleepGearV
R
(Covidien-Puritan Bennett) system
(Fig. 2C) can be changed from nasal pillows to a
nasal mask using the same bracket type of head
gear. When a nasal mask is fitted initially, the
straps are adjusted; but once in place the patient
should be able to use quick-release clips to take
the mask on and off. An alternative to clips is the
ability to slide the pre-adjusted straps in place to
improve ease of mask application. In the category
of oronasal masks, we have had the most success
with the Mirage QuattroTM (ResMed) full face
mask system Fig. 4A).
Conclusion
1 The nasal, nasal pillow, and oronasal mask inter-
faces (Figs. 2–4) can all be used with NIV ther-
apy for ALS patients.
2 Consider starting with a nasal pillow interface
(Fig. 3), as these interfaces are light-weight and
are the most comfortable. If the patient com-
plains of nasal irritation or air leaks despite nasal
pillow adjustment, then consider a light-weight
nasal mask interface (Fig. 2).
3 Choice of mask interface also depends on ease
of applying and removing the mask interface.
4 Masks/interfaces can be replaced as often as ev-
ery 6 months (per Medicare).
E. NIV- Ordering, Monitoring and Troubleshooting. Mask
Side Effects. In a cohort of 40 patients with
chronic respiratory failure from either pulmonary
or neuromuscular disease, the most common side
effects of NIV (bi-level PAP or portable ventilator)
included mouth or mask leaks in 43%, skin irrita-
tion at the face mask interface in 23%, nasal rhini-
tis or aerophagia in 13%, and discomfort from the
mask or headgear in 8%.48 Mask leaks that cause
air to blow in the eyes suggest the mask is too big
or fitted too loosely and needs to be refit and/or
re-sized. See Table 3 for trouble shooting measures
for NIV mask interfaces.
ALS patients with bulbar weakness are at an
higher risk for mouth leak. ALS patients with bul-
bar-onset disease and bulbar dysfunction are less
tolerant to NIV therapy.10,26,49,50 Although the
mechanisms of NIV intolerance in ALS patients
with bulbar dysfunction have not been systemati-
cally assessed, mouth leak from bulbar weakness is
a possible cause of intolerance. NIV requires the
tongue to be juxtaposed to the palate to prevent
upper airway pressure from escaping into the oral
cavity. Mouth leak has been associated with unin-
tentional awakenings resulting in sleep fragmenta-
tion51 that may impair NIV intolerance. The NIV
machine may sense the leak and compensate with
increased air pressure by means of the nasal mask
in an attempt to maintain adequate tidal volume.
This increased pressure applied to the nasal mu-
cosa may result in inflammation and increased
nasal resistance, diminished tidal volumes, and
NIV intolerance.52 ALS patients may not be aware
of mouth leak. Bed partners should be queried
about the patient opening his or her mouth with
NIV usage. Signs and symptoms of mouth leak may
include oral cavity insufflation with cheek expan-
sion, lip vibration as air escapes, nasal congestion,
or dry mouth. Treatment of mouth leak would
include a chin strap53 to prevent mouth opening
or use of a full face mask (Fig. 4). Once leak has
been minimized with either a chin strap or full
face mask, heated humidification should be used
to reduce nasal resistance and improve comfort.52
Sialorrhea is likely to be more common in ALS
FIGURE 4. Oronasal (Full Face) masks. (A) Mirage QuattroTM
(ResMed); (B) FormaTM (Fisher & Paykel Healthcare).
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patients with bulbar dysfunction and may decrease
NIV tolerance.54 The 2009 AAN practice parameter
provides the clinician with guidance regarding
treatments for sialorrhea.55
Ideally at the time of NIV initiation, the pro-
vider should allow the ALS patient to view and try
several NIV masks to determine which mask is
preferable. The ALS clinician may choose to have
a spare set of NIV masks in the ALS clinic for the
patient to view at the time NIV is ordered.
Difficulty Falling Asleep with NIV. Falling asleep
with a mask strapped to the head with an NIV
machine blowing air into the nose can be difficult
for patients. We first recommend assessing that the
mask is not leaking and is comfortable as outlined
in Table 3. To optimize initiation of sleep while
using NIV, the ALS patient may need a distraction.
We suggest listening to music or in some cases
watching television while the NIV is in place to
divert the patient’s attention away from NIV to
improve the initiation of sleep. The patient should
be instructed to put the NIV in place when signifi-
cantly sleepy to improve the likelihood of falling
asleep with NIV. This would include avoiding day-
time naps without the NIV that may reduce the
ability to fall asleep at bedtime with NIV. In some
patients prone to poor sleep initiation when start-
ing NIV, a sleep aid medication may be consid-
ered. Amitriptyline is a consideration, particularly
if it is also used to treat pseudobulbar symptoms
or sialorrhea. Trazodone or temazepam are alter-
native sleep aid medications. Once the patient
adjusts to NIV, the medication can be tapered. A
third method would be to initiate a ramp of the
pressure settings with the NIV machine. All bi-level
PAP machines have the ability to start IPAP at a
pressure lower than the target IPAP, to be ramped
up to the goal IPAP pressure over 10 to 45 min. As
the ALS patient adjusts to NIV, the ramp can be
shortened and eventually discontinued.
NIV Air Pressure Discomfort. The ALS patient
may complain that the NIV device provides positive
airway pressure when it is not wanted. Assess if the
patient was trying to talk, cough or yawn, as this
could result in enough air movement that the NIV
machine is triggered to provide IPAP. Instruct the
patient to avoid talking with NIV use until the
symptom resolves. If using S/T mode, decrease the
breath per minute rate or consider a trial of NIV
in S mode. If administering NIV with a mechanical
ventilator, decrease the sensitivity of the inspiratory
flow trigger.
The ALS patient may complain that the NIV
does not provide enough air pressure with inspira-
tion. Assess if the tubing is connected to the
machine and mask interface properly, assess if
there any holes in the tubing or mask interface
tubing, and replace as needed. Make sure the air
intake of the NIV machine is not blocked. If a bac-
terial filter is used, assess whether the filter is wet,
as this will obstruct air flow. Make certain the mask
interface is applied properly on the nose. If it is
not applied over the nose properly, the patient will
not receive adequate pressure support. Assess
whether the patient has nasal congestion and con-
sider medical treatment (see Table 3). If the above
are excluded, then consider an increase in IPAP
pressure, as the patient may have worsening respi-
ratory muscle function and require more pressure
support. If the patient complains that he or she
cannot exhale adequately while using NIV, reduce
EPAP to lowest possible setting, often 4 cm of
H2O.
The ALS clinician may initially troubleshoot
NIV intolerance by means of phone conversation.
However, if the patient has significant respiratory
Table 3. NIV trouble-shooting.
Problem Solution
Mask leak Refit or resize mask
Mouth leak Implement use of chin strap
Use oronasal (full face) mask that seals over both nose and mouth
Skin irritation at mask interface with the face Adjust fit if mask is too tight
Change to a smaller mask i.e. nasal pillow interface that has less facial contact
If skin breakdown is present - switch to a non-latex mask or implement
more frequent washing if using silicone mask
Nasal rhinitis and/or congestion Add heated humidification to reduce dryness
Nasal steroids to reduce mucosal swelling
Water dripping from mask/tube Adjust humidification system by reducing the heat setting
Place machine lower than the head of patient to keep water condensation
from flowing into mask
Aerophagia Simethicone to reduce abdominal discomfort and bloating
Reduce IPAP pressure as tolerated
Mask head gear discomfort Change head gear
Switch to mask with less pressure points on face i.e. nasal pillows
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symptoms, troubleshooting will require the clini-
cian to view the NIV machine and mask interface
to improve NIV tolerance and compliance with
therapy. If the clinician cannot troubleshoot the
NIV intolerance issue over the phone and the
patient is not unstable, the clinician should contact
the patient’s NIV medical equipment provider to
send a respiratory therapist to the patient’s home
to troubleshoot the NIV.
NIV Ordering. The initial NIV order requires
documentation of the diagnosis of ALS (ICD-9
335.20) and FVC <50%, or MIP <60 cm of H
2
O,
or PaCO2 45 mmHg to meet Medicare require-
ments. For bi-level devices, the initial order should
also state the mode (S or S/T) and the breath per
minute (BPM) rate if S/T mode is used, the mask
interface type, and humidification system. We also
routinely prescribe a chin strap. The respiratory
therapist setting up the NIV can determine the size
of the mask interface for the patient’s facial anat-
omy. If ordering a portable mechanical ventilator as
the NIV device there are more options for ventilator
mode. We frequently prescribe the synchronized
intermittent mandatory ventilation/pressure sup-
port (SIMV/PS) mode or the Assist Control mode
(A/C). The prescription should specify a pressure
support (equivalent to IPAP minus EPAP) and
PEEP (positive end-expiratory pressure) (equivalent
to EPAP), and respiratory rate (equivalent to breath
per minute rate) if desired. The respiratory thera-
pist setting up the portable mechanical ventilator
can then adjust the flow trigger and inspiratory and
expiratory times to optimize comfort.
NIV Usage Monitoring. ALS patient NIV compli-
ance should be assessed at each clinic visit. The
ALS clinician can obtain objective NIV usage infor-
mation by interrogating the NIV machine directly
or downloading information from a NIV data card
stored in the machine. Both the NIV machine and
data card provide information that differentiates
between usage hours, when the patient put on the
NIV mask and was breathing with the machine,
versus machine hours, when the NIV machine was
turned on but not used by the patient. The data
card provides more specific information about the
time of the day or night when NIV was used, aver-
age usage hours per day, number of days with
more than 4 hours of daily usage, etc. Download-
ing information from an NIV data card will require
device manufacture software to be downloaded on
a computer with a peripheral device that can read
the NIV data card. The NIV data card reports can
be stored either electronically and/or printed. The
ALS clinician may request the respiratory therapist
providing the NIV machine obtain the card data
for review. Once the data have been downloaded,
the data card can be re-used. One study demon-
strated that weekly NIV downloads were associated
with reduced ALS patient hospitalizations and
emergency department visits.56 Thus far it is
unclear if more frequent assessments of NIV usage
than routine clinic visits are beneficial to improve
NIV compliance or ALS patient quality of life and
survival. However, the ALS clinician should be
aware that NIV setting changes appear to be more
frequent within the first year after starting NIV8
and before the development of complete NIV com-
pliance defined as >6 h per 24-h period.56
Alternatively, many of the current bi-level NIV
devices have the capability to connect by means of
a modem to a Web-based data management system
provided by the NIV device manufacture. Exam-
ples of these data systems include EncoreAny-
whereTM by means of wired modem (Phillips
Respironics) and ResTraxxTM by means of wireless
module (ResMed). These electronic data systems
allow the ALS clinician to download NIV compli-
ance information as well as the ability to upload
NIV prescription changes to perform NIV therapy
by means of telemedicine. A recent study using the
GoodKnight 425ST bi-level NIV device (Tyco
Healthcare Group LP, California, USA) demon-
strated significantly reduced clinic and emergency
room visits and inpatient hospitalizations in those
ALS patients who used weekly telemonitoring of
NIV rather than standard clinic visit assessment
that consisted of one office visit 2–3 weeks after
starting NIV and every 3 months thereafter.56 The
authors did not find a difference in NIV compli-
ance or survival between the 2 groups, but the
study was a small, pilot study. Nevertheless, this
technology does currently exist. An interested ALS
clinician should contact the representative of the
NIV device manufacture and/or durable medical
equipment provider of the NIV device to set up a
web-based NIV data management system.
Conclusion
1 Many patients face NIV or NIV accessory chal-
lenges. There are simple solutions to many of
the problems, as outlined in Table 3.
2 Troubleshooting NIV requires the ALS clinician
to be knowledgeable about the equipment and
communicate with the respiratory therapist pro-
viding the NIV equipment.
3 NIV device usage should be assessed at clinic vis-
its. Weekly monitoring of NIV usage after device
initiation may avoid unnecessary hospitalizations
and emergency room visits.
II. MECHANICAL INSUFFLATION-EXSUFFLATION
Background. NIV assists weakened respiratory
muscles of inspiration to maintain adequate gas
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exchange. However, ALS patients may also develop
inadequate expiratory muscle function to perform
an adequate cough. The cough reflex requires
both inspiratory and expiratory muscle function
and is necessary to clear airway secretions that can
impair adequate airflow and subsequent gas
exchange. The cough reflex starts with a deep in-
spiration to generate insufflation of 85–95% of the
total lung capacity. The glottis and vocal cords
then close the airway. The abdominal muscles and
other expiratory muscles contract to further
increase the intrathoracic pressure, and air is
expelled rapidly with glottis and vocal cord relaxa-
tion. The air expelled with a cough can be meas-
ured as the peak cough expiratory flow (PCF), and
normal levels are greater than 6 L/s.57 PCF can be
easily measured in the clinic with a peak flow me-
ter. Alternatively, the PCF is measured with spirom-
etry as part of the FVC maneuver. In this situation,
the terminology changes, and the measurement
becomes a peak expiratory flow rate (PEFR) or
maximum forced expiratory flow (FEFMax) meas-
ured as either L/s or L/min.
Adequate cough expiratory flow of 2.7 L/s
(>160 L/min) has been reported as the minimum
requirement to be effective to clear the airway of
secretions and food particles in patients with neuro-
muscular diseases, including ALS.58,59 However, in
the setting of a respiratory tract infection, airway
secretions increase and an even higher PCF is need
to adequately clear the airway. In ALS patients a
PCF <4.25 L/s (<255 L/min) was predictive (P <
0.001) of an ineffective cough, defined as patient
self-report of inability to cough up mucus, abnor-
mal breath sounds, dyspnea or oxygen desaturation
during an upper respiratory tract infection.60 The
mechanical insufflation-exsufflation (MI-E) device
simulates a cough by first providing positive airway
pressure at a relatively high pressure of 40–45 cm
H
2
O for a few seconds to result in maximum inspi-
ration. The machine is then suddenly switched to
negative 40–45 cm H
2
O of airway pressure to gener-
ate a sudden, high volume of expiratory air flow
similar to a physiological cough to clear the airway
of secretions and mucus. The patient is instructed
to cough with exsufflation. In this way, the patient
will maximize synchrony with the MI-E by closing
the glottis at the end of inspiration to maximize in-
trathoracic pressure just before the forced expira-
tion. In ALS patients naı¨ve to NIV, MI-E signifi-
cantly increased mean PCF in both those with
severe bulbar symptoms, 178 to 212 L/min (a 19%
increase [P < 0.05]) and in those with few bulbar
symptoms, 217 to 264 L/min (a 21% increase [P <
0.001]). The increase was even more dramatic in
both bulbar (36% increase) and nonbulbar (60%
increase) ALS patients with PCF <160 L/min.61
The U.S. Food and Drug Association approved
the use of an MI-E device in 1993. Medicare and
private insurance companies often cover the cost
of MI-E in patients with a neuromuscular diagnosis
such as ALS and PCF <300–350 L/min (5–6 L/s).
Bach et al. demonstrated that patients with
severe respiratory muscle weakness from Duchenne
muscular dystrophy with a VC <1 liter and PCF
<4.5 L/s could be trained to use both NIV and
MI-E at home.58 Both NIV and MI-E were used as
needed if daytime oxygen saturation dropped
below 95%. Use of MI-E with NIV in this patient
population was associated with lower rates of hospi-
talization than patients using tracheostomy and
mechanical ventilation.58 A similar protocol of
combined NIV and MI-E used as needed to keep
daytime oxygen saturation above 94% reduced hos-
pitalizations in a cohort of 71 patients with a vari-
ety of neuromuscular disorders, including 4 with
ALS.62
MI-E Initiation. The provider should consider pre-
scribing MI-E when the PCF is less than 255–270
L/min (<4.25–4.5 L/s), and the ALS patient
reports symptoms of a respiratory tract infection,
inability to cough up mucus, or the ALS clinician
detects abnormal breath sounds (crackles). MI-E
may need to be avoided in ALS patients with
known bullous emphysema, pneumothorax, or
pneumomediastinum.
The MI-E machine circuit consists of an oro-
nasal mask attached to the machine with a single
tube and a bacteria/virus filter (Fig. 5). The MI-E
machine can be used with a tracheostomy with an
adapter. Inhalation pressures cannot be set higher
than exhaled pressures. The mask is held over the
nose and mouth with a good seal to prevent leaks.
The MI-E machine is switched, either manually or
automatically, to the inhale position for 2–3 s then
rapidly switched to the exhale position for 1–3 sec-
onds. The ALS patient is instructed to cough when
the machine is switched in the exhale position.
FIGURE 5. Mechanical insufflation-exsufflation device (Philips
Respironics).
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After exsufflation, the patient is given a 2- to 4-s
pause as the MI-E device is switched to the neutral
position to complete a single coughing cycle. This
process is then repeated for a total of 4–6 cough-
ing cycles to complete one MI-E sequence. After
an MI-E sequence the patient should rest for 30 s.
More than 6 cycles per MI-E sequence may put the
patient at risk of developing symptoms of hyper-
ventilation. A suction device may be needed to
remove thick secretions from the oral or upper air-
way. The patient then repeats this process for a
total of 4–6 MI-E sequences, resting between each
sequence, to complete a full MI-E treatment.
We recommend at least 3 to 4 MI-E treatments
a day with 5 MI-E sequences that each include 5
coughing cycles, with 1 treatment performed just
before bedtime or before NIV usage. With respira-
tory tract infections and symptoms of chest conges-
tion or mucus plugging, the treatments can be
increased to once or twice an hour to improve
symptoms and maintain oxygen saturations above
94%.62
MI-E Pressure Settings. When initiating MI-E ther-
apy, the initial pressure settings should be set to
þ15 for insufflations and 15 cm H
2
O for exsuffla-
tion, and gradually increased by 5 to 10 cm H
2
O
increments to a goal of þ40 and 40 cm H
2
O. A
minimum of þ35 and 35 are needed for com-
plete airway secretion removal. If needed, the pres-
sures can be increased further to a maximum þ60
and 60 cm H2O.
Winck et al. tested a variety of MI-E pressure
settings in a cohort of ALS patients.63 Thirteen
ALS patients were studied; 10 reported severe bul-
bar symptoms and 11 were using NIV. After 6
cycles of MI-E use at þ40/40, the mean PCF
increased from 170 to 200 L/min (P < 0.0005),
mean oxygen saturation increased from 94% to
98% (P < 0.005), and patients reported sympto-
matic improvement as measured by the Borg dysp-
nea score. Lower MI-E settings of þ15/15 and
þ30/30 cm H
2
O did not result in significant
improvement in PCF or oxygenation.
MI-E Intolerance. It is important for the provider
to understand that ALS patients with significant
bulbar dysfunction may have limitations that pre-
vent a maximal increase of PCF with MI-E. ALS
patients with advanced lower cranial motor neuro-
nopathies may have impaired closure of the glottis
and vocal cords. Impaired glottis closure will result
in inability to maintain adequate lung volumes
with insufflation. Therefore, the ALS patient with
inadequate glottis closure will never maintain a
large lung volume required for adequate expira-
tory air flow with exsufflation. Secondly, pharyn-
geal dilator muscles may become too weak to
maintain adequate force to keep the upper airway
open during exsufflation. The increased negative
airway pressure applied with exsufflation may cause
weakened pharyngeal dilator muscles to collapse
and thereby occlude airflow to prevent adequate
exsufflation.64 In these situations, tracheostomy
may need to be considered.
Conclusions
1 Consider using MI-E in asymptomatic ALS
patients with peak flow <160 L/min (2.7 L/s) to
assist in clearance of airway secretions and
debris.
2 Consider using MI-E in ALS patients with symp-
toms of impaired management of airway secre-
tions with peak flow <255–270 L/min (4.25–4.5
L/s).
3 Goal MI-E pressures are þ40 cm H2O for insuf-
flation and 40 cm H2O for exsufflation, given
that þ35/35 are the minimum pressures
needed to clear airway secretions, and þ40/40
significantly improve oxygen saturation and PCF
in ALS patients.
4 Initial prescription should include: Cough assist
device, 4 treatments a day and as needed, 5
coughing cycles per sequence followed by 30 s of
rest, and 5 sequences for each treatment. Initial
pressures of þ15 and 15 gradually increased to
a goal of þ40 and 40 cm H2O are reasonable.
5 In the setting of an upper respiratory tract infec-
tion, MI-E can be used to maintain daytime oxy-
gen saturation above 94%.
III. BREATH STACKING AND MANUAL ASSISTED
COUGH
Breath stacking and manually assisted cough tech-
niques are alternatives to MI-E to improve PCF.
With breath stacking, multiple inspiratory volumes
occur without expiration. The subsequent inspira-
tory volumes summate or stack to result in a larger
lung volume to be used with a subsequent sponta-
neous or manual assisted cough. Breath stacking
requires the patient be able to voluntarily close the
glottis between inspiratory efforts to prevent loss of
inspired volume. This may be difficult for the ALS
patient. Alternatively, expiration can be occluded
with a one-way valve that only allows airflow with
inspiration. With valved maneuvers, breath stack-
ing can increase inspired volumes by 15–20%.65
Given that inspiratory muscles are likely to be weak
when breath stacking is considered to augment
PCF, the inspired volumes can be manually pro-
vided with a resuscitation bag. The resuscitation
bag is connected by means of a short segment of
tubing to a one-way valve that is connected either
to a mouth piece or mask that goes over the nose
and mouth in the case of lip closure weakness.66
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Breath stacking has been demonstrated to increase
PCF in ALS patients by approximately 50 L/min,
and this effect lasted for 30 min after the proce-
dure.67 This is in agreement with a previous study
that demonstrated breath stacking improved mean
PCF from 1.81 L/s to 3.37 L/s in patients with a
variety of neuromuscular disorders.68 The manual
assisted cough technique requires a trained thera-
pist or family member to lean over the partially
supine patient, using one forearm to apply down-
ward pressure on the chest while the other hand
applies an abdominal thrust at the time of expira-
tion.57,69 The combination of breath-stacking and
manual assisted cough improves peak cough flow
more than breath-stacking alone.68,69 When MEP is
>34 cm H2O, manual assisted cough is inferior to
spontaneous cough, and the added benefit of
breath stacking may be diminished when MEP >34
cm H2O or VC >1.9 liters.
69 However, unlike man-
ual assisted cough, there is no ceiling effect with
breath stacking in that it does not appear to be in-
ferior to spontaneous cough when the patient has
a high MEP or VC.69 When VC is <340 ml, MEP
<14 H2O or unassisted PCF is <90 L/min these
manual methods are not likely to provide adequate
cough assistance, and MI-E should be consid-
ered.69 Additionally, when MI-E was compared
with combined breath stacking and manual
assisted cough, MI-E resulted in a significantly
higher mean PCF (7.47 L/s) than the combined
manual techniques (4.27 L/s).68 Manual assisted
cough can be labor intensive for the care provider,
should be avoided in patients with Greenfield fil-
ters, and should be used with caution in those with
recent abdominal surgery, abdominal feeding
tubes or at high risk of rib fractures.68 In contrast,
breath stacking appears to be without significant
side-effects. It is easy to administer with low cost
items, and it is more portable than an MI-E
machine.
Conclusions
1 Consider using valved breath stacking maneuvers
with or without manual assisted cough to
improve the clearance of airway secretions and
debris when MI-E is unavailable.
2 Manual assisted cough is not beneficial when
MEP >34 cm H2O.
IV. HIGH FREQUENCY CHEST WALL OSCILLATION
Another approach to assist with secretion clearance
is to apply mechanical forces to the chest wall to
physically loosen airway secretions, move them
from distal to more proximal airways and thereby
facilitate coughing them out. Manual chest percus-
sion with postural drainage is the traditional
approach to mobilize secretions, but this can be
very difficult for ALS patients with limited mobility
due to diffuse weakness. Additionally, manual
chest percussion places additional burdens on
caregivers. A newer method for secretion mobiliza-
tion is high frequency chest wall oscillation
(HFCWO). Several companies now manufacture
vests coupled to pneumatic compressors that
deliver rapidly reversing oscillatory pressure to the
chest wall. These high frequency chest wall oscilla-
tion vests have become standard for individuals
with cystic fibrosis70 but there is relatively limited
research on their use in ALS. Chaisson and col-
leagues performed a randomized trial of high fre-
quency oscillation in 9 subjects with ALS.71 They
did not find any significant differences in survival
or decline in FVC with high frequency chest wall
oscillation, though it is unlikely that this small
study was sufficiently powered to assess these end-
points. Lange, Lechtzin, et al. performed a multi-
center randomized trial of high frequency chest
wall oscillation in 46 individuals with ALS.72 They
found that subjects assigned to high frequency
chest wall oscillation had less breathlessness than
the control group. The 2009 AAN Practice Parame-
ter update stated there were insufficient data to
support or refute HFCWO for clearing airway
secretions in patients with ALS.14 Anecdotally,
some clinicians report a high rate of success com-
bining MI-E and high frequency chest wall oscilla-
tion. In theory this is a logical approach, but it has
not been systematically tested thus far.
V. DIAPHRAGM PACER
Investigators have considered the possible role of
diaphragmatic pacing stimulators (DPS), which
requires intramuscular implantation of electrodes
in ALS, to postpone the need for invasive mechani-
cal ventilation. A single study enrolled 16 patients
with ALS and provided percutaneous gastric feed-
ing tube and DPS placement simultaneously. The
mean FVC was 59%, and some used nocturnal NIV
at the time of DPS placement. The study showed
that the FVC rate of decline was 2.4% per month
before surgery and 0.9% per month after the sur-
gery.73 This very small, nonrandomized study sug-
gests the need for further study of diaphragmatic
pacing in the management of ALS. Given the lim-
ited data available, it is uncertain whether DPS is
helpful, harmful, or has no effect in ALS. DPS has
received FDA approval for a humanitarian use de-
vice exemption. With this type of FDA approval,
the device does not require scientific evidence of
efficacy to be marketed by the device manufacture.
The manufacture’s application, however, must con-
tain sufficient information for the FDA to
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determine that the device does not pose an unrea-
sonable or significant risk of illness or injury, and
that the probable benefit to health outweighs the
risk of injury or illness from its use.
Conclusions
1 Randomized, controlled trials are needed before
DPS should be adopted into routine clinical
practice.
2 DPS is not a replacement for NIV.
VI. TRACHEOSTOMY WITH MECHANICAL VENTILATION
When to Consider Tracheostomy With Mechanical Ven-
tilation. Tracheostomy with mechanical ventila-
tion should be considered urgently for symptoms
of respiratory failure when ALS patients are intol-
erant to NIV or despite maximal usage of NIV and
MI-E. Intolerance of NIV or failure of NIV is gen-
erally due to the inability to clear respiratory secre-
tions. This usually occurs in the setting of severe
bulbar weakness. When daytime pulse oximetry
remains <95% despite maximal therapy with NIV
and MI-E, 94% of ALS patients require tracheos-
tomy or die within the next 2 months.74 Therefore,
ALS patients should be engaged in conversation
regarding semi-urgent, elective tracheostomy with
mechanical ventilation when daytime oxygen satu-
ration is <95% despite maximal use of respiratory
therapies. If the ALS patient does not desire tra-
cheostomy with mechanical ventilation, then NIV
and MI-E therapies can be continued and addi-
tional comfort care initiated.
Before respiratory failure, the optimal time to
engage the ALS patient in a discussion regarding
tracheostomy and mechanical ventilation remains
uncertain. However, we make a point of trying to
have this conversation with all ALS patients so they
can make an informed decision and outline
advanced directives. It would be reasonable for the
ALS clinician to initiate a discussion regarding tra-
cheostomy when: (1) the patient uses NIV >12 h
in a 24-h time period (i.e., the patient is using NIV
more often than not using it) or (2) the patient is
intolerant of NIV, and FVC <50% or symptoms of
dyspnea. ALS patients may directly ask what to
expect at the end of life and consider tracheos-
tomy out of fear of suffocating to death. However,
when caregivers are queried, they report a majority
of ALS patients, 63–98%, die peacefully.75–77
Slightly less than a third of patients were alert and
communicating shortly before death while the ma-
jority, 73%, were asleep or unresponsive77 presum-
ably from hypoxic-hypercarbic encephalopathy.
Symptoms of dyspnea and anxiety are reported in
25–36% of ALS patients75,77 and may require treat-
ment with benzodiazepines and/or morphine. We
find sharing this information is important to allevi-
ate any misconceptions about the end-stages of
ALS.
ALS Patient Factors Associated With Undergoing
Tracheostomy. ALS patients undergoing tracheos-
tomy are more often men, younger, have higher
income, have young children or hold the belief
that choosing a tracheostomy would allow for
future treatments that may cure the disease.75,78–81
Tracheostomies are often initiated in an emergent
situation.75,78,79,81,82 This may be because ALS
patients who undergo tracheostomy do not have
advanced directives82 and are less likely to receive
information about impending respiratory failure.79
However, it can be a difficult decision for some
ALS patients to decide upon elective tracheostomy
and the decision is put off until acute respiratory
failure develops.
ALS Patient Outcomes After Tracheostomy.
Survival. Although tracheostomy with mechan-
ical ventilation will avoid death from respiratory
failure, it is not associated with indefinite survival.
When tracheostomy is initiated for respiratory fail-
ure, the median survival ranges from <12 months
to 37 months.75,81–83 The most common cause of
death is respiratory tract infections.81–83 The tra-
cheostomy site itself is a conduit for respiratory
tract infections, and despite the use of a mechani-
cal ventilator, mucus plugs and removal of excess
secretions may become problematic. In a multivari-
able analysis use of enteral nutrition, age <45
years, follow-up at an ALS center, and being mar-
ried were associated with longer survival after
tracheostomy.81
Quality of Life. When ALS patients are queried
after tracheostomy, a vast majority, >80%, report a
positive perception of tracheostomy with ventila-
tion, indicate they would have the procedure
again, and recommend it to other ALS
patients.78,79,82,84 ALS patients with tracheostomy
were more satisfied living at home78 and reported
more happiness if they were able to communicate
or leave their home to participate in social activ-
ities.84 However, one study reported that over 3
years’ time there was a modest decrease in overall
quality of life satisfaction after tracheostomy.80
Over time, as many as 50–70% of ALS patients
with tracheostomy will have minimal communica-
tion ability or become locked-in.80,85 One study
noted that 42% of ALS patients would want to stop
long-term mechanical ventilation if they lose the
ability to communicate, and most patients wanted
to place limits on long-term mechanical ventilation
with advanced directives.78 Advanced planning is
likely to have a beneficial effect on communication
between the patient and caregivers.78 Additionally,
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although a majority of ALS patients reported they
were satisfied with tracheostomy, as many as 20%
were not satisfied and requested that the ventilator
be discontinued. In this scenario the ALS clinician
may be in the position of discontinuing mechani-
cal ventilation per the request of the ALS patient.
If patient consent for tracheostomy ventilation is
withdrawn and terminal weaning from the ventila-
tor is initiated, Borasio and Voltz recommend seda-
tion with a bolus of 2–4 mg midazolam before ven-
tilator discontinuation then a bolus of 5–10 mg of
morphine followed by a morphine infusion of half
of the bolus dose per hour during the ventilator
weaning with repeated bolus or increased infusion
rate as needed for any signs of distress.86
In contrast to ALS patients, caregivers of
patients who receive home mechanical ventilation
with tracheostomy report decreased quality of life
and express a great deal of frustration and unhap-
piness.78–80,84 Caregiver distress continued despite
full-time aides,80 with 30% of caregivers reporting
lower quality of life than the ALS patients for
whom they provided care. Only 50% would con-
sider tracheostomy for themselves.79 Caregivers
who spent time outside of the home and took care
of their own needs were more likely to adjust.84
Conclusions
1 Daytime oxygen desaturation <95% in patients
using optimized NIV and MI-E is a useful indicator
of impending respiratory failure and considera-
tion of tracheostomy with mechanical ventilation.
Battery operated finger pulse oximeters can be
purchased for a nominal fee for home use.
2 After tracheostomy with mechanical ventilation
for respiratory failure, median ALS patient sur-
vival is around 1–3 years. Respiratory infections
are the most common cause of death.
3 Most ALS patients who underwent tracheostomy
would choose the procedure again, but quality
of life and ability to communicate effectively may
wane over time. Advanced directives before tra-
cheostomy likely improve communication and
preserve ALS patient autonomy.
4 Caregivers of ALS patients with tracheostomy
and mechanical ventilation report poor quality
of life and may require significant psychosocial
support.
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